The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SION | +130.67% | N/A | N/A | +50% |
| S&P | +17.78% | +74.31% | +11.75% | +13% |
Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.
After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025.
This clinical-stage biotech focused on cystic fibrosis therapies reported a notable insider sale amid a year of sharp ownership reductions.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$152.00K | 9.0% |
| Market Cap | $1.84B | 0.0% |
| Market Cap / Employee | $31.12M | 0.0% |
| Employees | 59 | 43.9% |
| Net Income | -$20,440.00K | -29.0% |
| EBITDA | -$23,460.00K | -30.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $58.45M | 54.7% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $7.41M | -14.6% |
| Short Term Debt | $1.27M | 18.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -29.31% | 22.6% |
| Return On Invested Capital | -64.56% | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$16,830.00K | -42.5% |
| Operating Free Cash Flow | -$16,626.00K | -41.1% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.82 | 2.17 | 3.86 | 5.69 | - |
| Price to Tangible Book Value | -2.82 | 2.17 | 3.86 | 5.69 | - |
| Enterprise Value to EBITDA | -10.31 | -23.55 | -45.07 | -68.74 | - |
| Return on Equity | -61.4% | -28.1% | -31.8% | - | |
| Total Debt | $9.50M | $9.24M | $8.97M | $8.68M | -11.00% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
